Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

NSGS mice humanized with cord blood mononuclear cells show sustained and functional myeloid-lymphoid representation with limited graft-versus-host disease

  • Panisello, Carla|||0000-0002-8437-4418
  • Aschero, Rosario
  • Martnez-Moreno, Alba
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Falgàs, Aïda|||0000-0002-5040-2265
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Carabelli, Julieta|||0000-0003-2329-3996
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Lázaro-Díez, María|||0000-0002-6098-8052
  • Prado, Julia G.|||0000-0002-5439-4645
  • Blanco, Julià|||0000-0002-2225-0217
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Juan, Manel|||0000-0002-3064-1648
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Humanized immunodeficient mice serve as critical models for investigating the functional interplay between transplanted human cells and a pre-reconstituted human immune system. These models facilitate the study of molecular and cellular pathogenic mechanisms and enable the evaluation of the efficacy and toxicity of immunotherapies, thereby accelerating their preclinical and clinical development. Current strategies rely on inefficient, long-term/delayed hematopoietic reconstitution by CD34+ hematopoietic progenitors or short-term reconstitution with peripheral blood mononuclear cells (PB-MNCs) associated with high rates of graft-versus-host disease (GvHD) and an inefficient representation of immune cell populations. Here, we hypothesized that immunologically naïve cord blood mononuclear cells (CB-MNCs) could serve as a superior alternative, providing long-lasting and functionally effective immune reconstitution. We conducted a comprehensive comparison between the non-obese diabetic (NOD).Cg-Prkdc∧ˆscid-IL2rg∧ˆtm1Wjl/SzJ (NSG) and NSG-Tg(CMV-IL3,CSF2,KITLG)∧ˆ1Eav/MloySzJ (NSGS) immunodeficient mouse models following humanization with either PB-MNCs or CB-MNCs. We assessed the engraftment dynamics of various human immune cells over time and monitored the development of GvHD in both models. For the most promising model, we extensively evaluated immune cell functionality in vitro and in vivo using sarcoma and leukemia xenografts. Humanizing NSGS mice with CB-MNCs results in a rapid, robust, and sustained representation of a diverse range of functional human lymphoid and myeloid cell populations while minimizing GvHD incidence. In this model, human immune cell populations significantly impair the growth and engraftment of sarcoma and B-cell acute lymphoblastic leukemia cells, with a significant inverse correlation between immune cell levels and tumor growth. This study establishes a fast, efficient, and reliable in vivo platform for various applications in cancer immunotherapy, particularly for exploring the complex interactions between cancer cells, immune cells, and the tumor microenvironment in vivo, prior to clinical development.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  • Guerrero Murillo, Mercedes
  • Marchese, Domenica, 1986-
  • Heyn, Holger
  • Menéndez, Pablo
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response., Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

  • Falgàs, Aïda
  • Lázaro-Gorines, Rodrigo
  • Zanetti, Samanta Romina
  • Rubio-Pérez, Laura
  • Martínez-Moreno, Alba
  • Vinyoles, Meritxell
  • Guerrero-Murillo, Mercedes
  • Fernández-Fuentes, Narcís
  • Roca-Ho, Heleia
  • Tirado, Néstor
  • Panisello, Carla
  • Velasco-Hernández, Talia
  • Mayado, Andrea
  • Pérez-Pons, Alba
  • Genescà, Eulàlia
  • Ribera, Josep-Maria
  • Ribera, Jordi
  • Camós, Mireia
  • Ramírez-Orellana, Manuel
  • Anguita, Eduardo
  • Ballerini, Paola
  • Fuster, José Luis
  • Juan, Manel
  • González-Navarro, Azucena
  • Locatelli, Franco
  • Stam, Ronald W.
  • Querol, Sergi
  • Velasco, Pablo
  • Ortiz-Maldonado, Valentín
  • Martínez-Cibrián, Nuria
  • Delgado, Julio
  • Orfao, Alberto
  • Álvarez-Vallina, Luis
  • Bueno, Clara
  • Menéndez, Pablo
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease with dismal prognosis. Despite the revolutionary impact of CD19-directed chimeric antigen receptor (CAR19) T-cell therapy, >50% of patients relapse within a year. Both leukemia cell–intrinsic factors favoring immune escape and poor CAR T-cell persistence contribute to clinical failure. Moreover, the expression of immune checkpoint receptors (ICRs) and their ligands within the bone marrow (BM) microenvironment may contribute to leukemia progression and therapy resistance. Here, we characterized the expression of ICRs and their ligands in leukemic blasts, T cells, and mesenchymal stromal cells (MSCs) from B-ALL BM samples at diagnosis and relapse, comparing them with age-matched healthy BM controls. Our findings reveal a significantly upregulated expression of TIM-3 in T cells and its ligand, galectin-9, in both blasts and MSCs throughout disease progression. The expression of galectin-9 in B-ALL blasts and TIM-3 in CAR19 T cells negatively correlates with clinical outcome. Furthermore, we demonstrate that galectin-9 impairs CAR19 T-cell homeostasis and cytotoxicity. Notably, an engineered TIM-3–Fc decoy receptor, delivered either by primary T cells coadministered with CAR19 T cells or via a bicistronic all-in-one CAR19–TIM-3–Fc construct, improved the antileukemia efficacy and persistence of CAR19 T cells in B-ALL xenograft models. Mechanistically, CAR19–TIM-3–Fc T-cell treatment promotes the in vivo expansion of transduced and bystander effector and memory T cells, as determined by spectral flow cytometry. Collectively, these TIM-3–Fc decoy–armored CAR19 T cells offer a promising therapeutic strategy for patients with R/R B-ALL., Samples included in this study were provided by the collection of samples of the Josep Carreras Leukemia Research Institute (C002922) and were processed following standard operating procedures with the appropriate approval of the Ethics and Scientific Committees. Core support of research in the P.M. laboratory is provided by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa; additional support is provided by the European Research Council (grants ERC-PoC-957466 IT4B-TALL and ERC-PoC-101100665 BiTE-CAR); Horizon 2020 (grant 101057250-CANCERNA), the Ministerio de Economía, Industria y Competitividad (MINECO; grants PID2019-108160RB-I00 and PID2022-142966OB-I00/MCIN/AEI/10.13039/501100011033 and Feder Funds), MINECO/European Union NextGenerationEU (grants CPP2021-008508 and CPP2022-009759); the Spanish Association Against Cancer (AECC; grants PRYGN234975MENE, and PRYGN211192BUEN), the Health Institute Carlos III (ISCIII; grant PI20/00822), the Uno Entre Cien Mil Foundation, Dutch Josep Carreras Leukemia Stifftung (DJCLS; grant 02 R/2023), MINECO (grant PLE2021-007518), and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). Research in the L.Á.-V. laboratory is funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/ 501100011033 (grants PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021-121711-100, CPP2022-009762, and CPP2022-009765); the ISCIII/FEDER (grants DTS20/00089 and PMPTA22/00167), the AECC (grants PROYE19084ALVA and PRYGN234844ALVA); the CRIS Cancer Foundation, Spain (grants FCRIS-2021-0090 and FCRIS-2023-0070); the Fundación “La Caixa” (grant HR21-00761 project IL7R_LungCan); the Comunidad de Madrid (grant P2022/BMD-7225 Next Generation CART MAD), and the Fundación d'Estudis i Recerca Oncológica (BBASELGAFERO2024.01). A.F. was supported by a Juan de la Cierva postdoctoral fellowship (FJC2021-046789-I); N.T. was supported by a PhD fellowship (FPU19/00039) from the Spanish Ministry of Science and Innovation; and C.P. was supported by a Contratos predoctorales de formación en investigación en salud fellowship (FI21/00161) from ISCIII. L.R.-P. is supported by a predoctoral fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck. S.R.Z. was supported by a Marie Sklodowska Curie Fellowship (GA 795833)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias

  • Guerrero Murillo, Mercedes
  • Marchese, Domenica, 1986-
  • Heyn, Holger
  • Menéndez, Pablo
The impact of phenotypic, clonal, and functional heterogeneity of chimeric antigen receptor (CAR)-T cells on clinical outcome remains understudied. Here, we integrate clonal kinetics with transcriptomic heterogeneity resolved by single-cell omics to interrogate cellular dynamics of non-transduced (CARneg) and transduced (CARpos) T cells, in the infusion product (IP) and at the CAR-T cell expansion peak in five B cell acute lymphoblastic leukemia (B-ALL) patients treated with CD19CAR-T cells (varni-cel). We identify significant differences in cellular dynamics in response to therapy. CARpos T cells at IP of complete response patients exhibit a significantly higher CD4:CD8 ratio, validated in a larger cohort B-ALL patients (n = 47). Conversely, at the expansion peak, there is a clonal expansion of CD8+ effector memory and cytotoxic T cells. Cytotoxic CARpos γδ-T cells expansion correlates with treatment efficacy validated in a cohort of B-ALL (n = 18) and diffuse large B cell lymphoma (DLBCL) patients (n = 58). Our data provide insights into the complexity of T cell responses following CAR-T cell therapy and suggest drivers of immunotherapy response., Research in P.M./C.B. laboratory was supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the European Research Council grants (ERC-PoC-957466, ERC-PoC-101100665), H2020 (101057250-CANCERNA), the Fight Kids Cancer Foundation (Cure2MLL project), the Spanish Research Agency (AEI) (PID2022-142966OB-I00 funded by MCIN/AEI/10.13039/501100011033; FEDER Funds; CPP2021-008508, CPP2021-008676, and CPP2022-009759 funded by MICIU/AEI/10.13039/501100011033; and the European Union NextGenerationEU/PRTR), Ayudas Merck de Investigación from Health Merck Foundation, the Spanish Association Against Cancer (AECC, PRYGN234975MENE), and the ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resilencia). Additional funding was provided to C.B. by AECC (PRYGN211192BUEN), the Uno Entre Cien Mil Foundation, AIE (MINECO PLE2021-007518), Deutsche José Carreras Leukämie-Stiftung (DJCLS/02R/2023), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822 and PI24/00763).